PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50123F61005Purpose of THIS modification IS to — Glaxosmithkline LLC

Glaxosmithkline LLC holds $3.0B across 194 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent 75A50122D00002. Recompete timing centers on the Dec 31, 2027 PoP end — agencies typically plan 12–18 months ahead.

Barda - Aspr / Daappo / Barda Dcma
Awarding office
Glaxosmithkline LLC
Recipient
Dec 31, 2027
PoP end
$171.6M
Obligated
541714
NAICS
AN12
PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Glaxosmithkline LLC — $90

Contract facts

Federal
Contract number75A50123F61005
Also listed as75A50122D00002-75A50123F61005
AgencyBarda - Aspr / Daappo / Barda Dcma
Awarding officeBarda - Aspr / Daappo / Barda Dcma
IncumbentGlaxosmithkline LLC
UEIFRHTPHMZMX47
NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN12
Parent IDIQ / IDV75A50122D00002
Place of performanceMARIETTA, PA
PoP end (current)Dec 31, 2027
Obligated$171.6M

PURPOSE OF THIS MODIFICATION IS TO: 1. ACCEPT TRANSFER ACCOUNTABILITY OF 5,015,690 VIALS (50.1 MILLION DOSES) OF AS03 A… is a federal award for Barda - Aspr / Daappo / Barda Dcma held by Glaxosmithkline LLC. Estimated value $171.6M ($171.6M obligated). Current period of performance ends Dec 31, 2027. Place of performance: MARIETTA, PA.

PURPOSE OF THIS MODIFICATION IS TO: 1. ACCEPT TRANSFER ACCOUNTABILITY OF 5,015,690 VIALS (50.1 MILLION DOSES) OF AS03 ADJUVANT FROM CONTRACT # W15QKN-20-C-0048 TO CONTRACT # 75A50122D00002 2. ADD FUNDING IN THE AMOUNT OF $1,038,708.00 FOR 33 BUL

Recompete timing

Public
Expiring in 498 days

Current PoP ends Dec 31, 2027 (498 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Jul 1, 2026.

Incumbent footprint

Public record

Glaxosmithkline LLC$3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($3.0B) · all agencies
Department of Health and Human Services (HHS)$3.0B · 100%Department of Defense (DOD)$1.7M · 0%Department of Veterans Affairs (VA)$1.5M · 0%Department of State (DOS)$1.2M · 0%
Open full company profile

Related awards

Same parent · incumbent
75A50126F61020
TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIORI…
Department of Health and Human Services (HHS) · GLAXOSMITHKLINE LLC
$493K
Oct 29, 2026
75A50124F61014
THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL …
Department of Health and Human Services (HHS) · GLAXOSMITHKLINE LLC
$18.4M
Feb 21, 2027
75A50124F61013
THE PURPOSE OF THIS TASK ORDER IS TO ESTABLISH FILL/FINISH ACTIVITIES FOR ADJUVANT (AS03) …
Department of Health and Human Services (HHS) · GLAXOSMITHKLINE LLC
$15.4M
Feb 21, 2027
75A50124F61010
THE PURPOSE OF THIS TASK ORDER IS TO PROCURE STORAGE AND STABILITY FOR ANTIGENS AND ADJUVA…
Department of Health and Human Services (HHS) · GLAXOSMITHKLINE LLC
$40.9M
May 21, 2027
75A50124F61012
THE PURPOSE OF THIS HHS TASK ORDER IS TO PROCURE SERVICES FOR THE STORAGE AND STABILITY OF…
Department of Health and Human Services (HHS) · GLAXOSMITHKLINE LLC
$14.0M
May 21, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 75A50123F61005?

75A50123F61005 (Purpose of THIS modification IS to) is a Barda - Aspr / Daappo / Barda Dcma award with an estimated value of $171.6M, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50123F61005?

Barda - Aspr / Daappo / Barda Dcma awarded 75A50123F61005 to Glaxosmithkline LLC.

Who is the incumbent on 75A50123F61005?

Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Dec 31, 2027.

When does Glaxosmithkline LLC’s 75A50123F61005 come up for recompete?

SCOUT tracks a period-of-performance end of Dec 31, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75A50123F61005